Tolperisone Hydrochloride

SAN DIEGO, Nov. 24, 2021 /PRNewswire/ --Neurana Pharmaceuticals, Inc. a biotechnology company focused on the treatment of neuromuscular conditions, today announced that Craig Thompson, President and Chief Executive Officer, will present at the 33rd Annual Piper Sandler Healthcare Conference and participate in one-on-one meetings with investors. The conference takes place virtually November 29th – December 2nd. Presentations will be available for registered attendees via the Piper Sandler conference site. About Neurana Pharmaceuticals, Inc. Neurana Pharmaceuticals, Inc. is a privately held, clinical-stage, biotechnology company focused on the treatment of neuromuscular conditions, including acute, painful muscle spasms of the back. The company was founded in 2013 and is based in San Diego. Neurana's lead development compound is tolperisone, a novel, non-opioid, non-drowsy, non-cognitive impairing treatment, which the company is developing for the large population of patients who experience muscle spasms. For additional information, please visit .

The Drugs Controller General (India) has directed the State drug controllers to restrict the fixed dose combination (FDC) tolperisone HCI 150 mg+ paracetamol IP 500 mg tablet only for symptomatic treatment of post-stroke spasticity associated with pain in adults, and direct the manufacturers to submit phase IV clinical trial data on revised indication. The decision comes nine years after a Parliamentary Standing Committee (PSC) decided to refer the FDC to New Drug Advisory Committee (NDAC)/Subject Expert Committee (SEC) for examination and review related to its continued marketing and updation of product monograph in light of recent knowledge and regulatory changes in overseas. The tablet was initially approved by the DCGI on October 21, 2010, for the treatment of patients with acute painful musculoskeletal conditions. The PSC’s decision was on May 8, 2021. The Committee in its report included the combination among 13 drugs which did not have permission for sale in any of the major developed countries such as the United States, Canada, Britain, European Union nations and Australia and none of these drugs have any special or specific relevance to the medical needs of India. The FDC mentioned in the report was from Themis Medicare. The matter was discussed in 26th SEC (Analgesic and Rheumatology) meeting held on September 8, 2016 when it was reviewed in the light of the recommendation of the PSC regarding its continued manufacturing and updation of product monographs in the wake of recent knowledge and regulatory changes overseas. The SEC recommended that the FDC should be marketed only for symptomatic treatment of post-stroke spasticity associated with pain in adults. Besides, the firm should conduct a Phase IV study on the recommended revised indication. Accordingly, the protocol shall be submitted for further review and the firm was asked to revise their package insert accordingly. The initial applicant was asked to conduct the phase IV clinical trial. However, the firm surrendered the original product permission on September 10, 2017, said the drug regulator in a letter on Wednesday.